Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win
Bristol Myers Squibb stock gapped higher Friday after the Big Pharma stalwart beat June-quarter forecasts and raised its outlook.
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Bristol Myers Squibb stock gapped higher Friday after the Big Pharma stalwart beat June-quarter forecasts and raised its outlook.